FDA OKs Sanofi drug for previously treated multiple myeloma

The FDA approves Sanofi’s (SNY +4%) Sarclisa (isatuximab-irfc), combined with Bristol-Myers Squibb’s (BMY +1.7%) Pomalyst (pomalidomide) and dexamethasone, for adult multiple myeloma (MM) patients who have received at least two prior lines of therapy, including lenalidomide (Revlimid) and a proteasome inhibitor. The agency’s action date was April 30.

Isatuximab is a monoclonal antibody that promotes programmed tumor cell death via targeting a specific epitope on the CD38 receptor. CD38 is a protein found on the surface of white blood cells.

Related product: Johnson & Johnson’s (JNJ +2.4%) Darzalex (daratumumab), also a C38-directed cytolytic antibody used to treat MM.

https://seekingalpha.com/news/3547590-fda-oks-sanofi-drug-for-previously-treated-multiple-myeloma